ResMed Inc.

ResMed — Business Economics

Ticker: RMD | Currency: USD | Most recent data: FY2025 10-K (ended June 30, 2025)

ResMed operates a medtech razors-and-blades model anchored in treating obstructive sleep apnea (OSA), a condition affecting ~936 million people globally with less than 20% diagnosed. The economic engine has been strengthening materially.

How it makes money. Two segments: (1) Sleep and Breathing Health (~90% of revenue) — CPAP/BiPAP devices (the "razor") plus masks and accessories (the "blade") that require replacement every 3–6 months, generating sticky recurring revenue. (2) Residential Care Software (~10%) — SaaS platforms (Brightree, MatrixCare) serving home medical equipment providers, skilled nursing, and hospice, creating workflow lock-in. The mask/accessories stream is the higher-margin, higher-growth component, and management has deliberately shifted the mix toward it.

Strengthening engine. Revenue has compounded from ~$3.2B (FY2022) to ~$4.7B (FY2024) and likely exceeded $5B in FY2025 (the company grew headcount from 9,980 to 10,600+). Philips's 2021 CPAP recall handed ResMed a once-in-a-generation share gain that is now converting into a durable installed base advantage — every new ResMed device placed generates years of mask resupply revenue. Gross margins run ~59% with operating margins above 30%, and both have been expanding as mask mix increases.

Win-win alignment. Patients get effective, non-invasive treatment for a life-threatening condition. Payers benefit because untreated OSA drives costly comorbidities (hypertension, stroke, heart failure). ResMed's cloud-connected platform (myAir, AirView) improves therapy adherence, which keeps all parties happy and protects reimbursement.

Key governing metrics: new patient device setups, 90-day therapy adherence rates, mask resupply attach rates, and SaaS ARR growth. No signs of deterioration — every segment is growing and the addressable market remains massively underpenetrated. The GLP-1 drug risk (weight loss reducing OSA prevalence) is real but unlikely to materially impair the business given the sheer size of the undiagnosed population and the fact that moderate weight loss often does not eliminate the need for CPAP.

Market Overview — ResMed Inc.

ResMed operates in a structural growth market with an enormous undiagnosed patient pool, a consolidated competitive landscape tilted in its favor, and secular tailwinds that dwarf the GLP-1 headwind narrative.

The market: sleep-disordered breathing (SDB) and respiratory care. An estimated 936 million adults globally have obstructive sleep apnea (OSA), per a landmark Lancet study. Even in developed markets, only ~20% are diagnosed, and a fraction of those are on therapy. This makes SDB one of the most underpenetrated chronic disease categories in medtech — the problem is not demand but awareness and diagnosis infrastructure. The global CPAP/BiPAP device and mask market is roughly $10–12 billion and growing at a high-single-digit CAGR, driven by rising obesity, aging demographics, and expanding home-based testing.

Competitive landscape: a duopoly with a wounded incumbent. The flow generator market has been a ResMed–Philips Respironics duopoly for decades. Philips' June 2021 recall of 5.5 million devices (degraded sound-abatement foam) effectively removed ~40% of global supply for years. ResMed captured that share and is converting it into a sticky installed base generating recurring mask revenue. Philips is re-entering but faces consent-decree constraints, brand damage, and a rebuilt channel — recapturing meaningful share will take years. Fisher & Paykel Healthcare is a credible #3 in masks but remains subscale in devices.

GLP-1 overhang is misunderstood. Weight loss reduces apnea severity but does not cure moderate-to-severe OSA, which is the therapy population. Moreover, GLP-1 adoption increases healthcare engagement, potentially accelerating diagnosis of the massive undiagnosed pool. ResMed's own data shows new patient starts have increased alongside GLP-1 adoption.

ResMed's moat is multi-layered, actively widening, and anchored in the hardest advantages for competitors to replicate.

Switching costs are the core. Once a patient is titrated on a ResMed device, mask replacements (30–40% of revenue) must be ResMed-compatible. DMEs build billing, resupply, and compliance workflows around ResMed's AirView cloud platform (~18M+ connected devices). Ripping that out is operationally painful and clinically risky.

Data compounds the advantage. Billions of nights of respiratory data feed machine-learning algorithms that improve auto-titration, predict non-compliance, and enable remote patient management. No new entrant can bootstrap this dataset.

Regulatory barriers are real but table-stakes — FDA 510(k) clearance is necessary but not sufficient. The Philips recall proved the moat's power: when a duopoly partner stumbled, ResMed captured share that is now locked in via switching costs and mask annuities. Philips' re-entry faces a ResMed installed base dramatically larger than 2020.

GLP-1 risk is overstated. ~60% of OSA patients are non-obese; weight loss reduces severity but rarely eliminates it.

ResMed's financial profile is elite among medtech peers. ROIC has run consistently above 20% — roughly double the sector median and well clear of any reasonable cost-of-capital estimate. These returns are structurally embedded: the razors-and-blades model means each device placed generates years of high-margin mask replacements with minimal incremental capital. Gross margins have expanded toward 60% as the Philips windfall matured into a higher-margin installed base.

Debt usage is conservative. The company levered up modestly for software acquisitions (Brightree, MEDIFOX DAN, MatrixCare) but has been rapidly deleveraging — net debt/EBITDA sits well below 1x. The pending MatrixCare divestiture for $490M further strengthens the balance sheet while sharpening focus. Sleep therapy is medically necessary and non-discretionary, meaning cash flows remain resilient even through severe downturns; debt service is never in question.

Earnings quality is clean. FCF conversion has consistently matched or exceeded net income — no aggressive accruals or working capital manipulation. Goodwill (~$3B from software acquisitions) is the one balance-sheet item to monitor, but the MatrixCare sale signals disciplined capital recycling rather than impairment risk. No auditor changes, no related-party red flags, and a diversified global customer base with no material concentration.

Runway for Reinvestment

ResMed's reinvestment runway is long but the channel is narrow — the business generates more cash than it can organically redeploy, and management's M&A track record outside the core has been value-destructive.

The organic opportunity is exceptional. With ~80% of the estimated 936 million global OSA sufferers undiagnosed, ResMed can grow the core sleep business for decades by simply expanding awareness, diagnosis rates, and geographic penetration. R&D spend (~7% of revenue) earns extraordinary returns: each AirSense platform generation drives multi-year upgrade cycles with 60%+ gross margins. ROIC on the core device/mask business has consistently exceeded 25%.

Capital allocation, however, is the weak link. Management diversified into residential care software — acquiring MatrixCare (~$750M, 2018) and MEDIFOX DAN (~€1B, 2022) — only to announce the sale of MatrixCare in June 2026 for $490M, crystallizing a ~$260M loss. This pattern reveals a recurring overreach into adjacencies that dilute returns.

The implied organic reinvestment rate is low (~13% capex/FCF), reflecting the asset-light model. Most excess cash flows to shareholders via buybacks and dividends — sensible when organic ROIC dwarfs acquisition returns. The shrinking share count (from ~148M to ~144M over two years) has been accretive.

The critical question is whether management will resist the temptation to do another large SaaS acquisition with the ~$490M MatrixCare proceeds. The Noctrix acquisition (restless legs syndrome, June 2026) is a more sensible bolt-on — adjacent to sleep, clinically synergistic, and small.

ResMed is the clear category leader in sleep-disordered breathing, and the competitive gap has widened materially since Philips Respironics' 2021 recall. Philips has re-entered with DreamStation 2 but is rebuilding from a structurally diminished position — lost clinician relationships and distribution don't snap back. ResMed's device installed base keeps compounding mask and accessory pull-through, where Fisher & Paykel Healthcare is the primary rival but lacks a comparable flow-generator platform. Inspire Medical offers a surgical implant for CPAP-intolerant patients — a complementary niche, not a head-on competitor.

ResMed's digital ecosystem (myAir, AirSense 11 cloud connectivity) creates a data and workflow moat that no peer matches, locking in DME providers and sleep clinics.

ResMed's dominance is durable: it owns the largest installed base, the best-connected digital platform, and the highest device share in a structurally growing market. The GLP-1 drug concern (weight loss reducing OSA prevalence) has proven overblown — diagnosed patients still require airway therapy and weight loss actually improves CPAP adherence, expanding the funnel.

Management & Shareholder Orientation

ResMed benefits from founder-family continuity — Mick Farrell, son of founder Peter Farrell, has led as CEO since 2013, providing long-horizon strategic consistency rare in medtech. Insider ownership in percentage terms is modest (~1–2% for all directors and officers combined), typical for a $35B+ company, but the dollar value represents hundreds of millions — meaningful alignment.

Capital allocation signals discipline: the announced $490M MatrixCare divestiture (June 2026) shows willingness to prune non-core assets to sharpen focus on sleep and breathing health. Dividends have grown consistently, supplemented by share buybacks ($46.8M treasury shares outstanding). Compensation leans on performance-based equity, tying executive wealth to shareholder outcomes.

The board is majority independent. No material regulatory actions against leadership. No related-party transaction concerns. Institutional ownership is dominated by passive giants (Vanguard, BlackRock, Capital Group) — no activist or concentrated long-term holder providing external governance pressure, which is a minor gap.

Insider selling has followed routine 10b5-1 plan patterns — no distress signals.

ResMed's management has been operationally excellent in the core sleep business but stumbled on software M&A. Mick Farrell (CEO 2013–2025) navigated two major industry disruptions — the 2021 Philips recall and the 2023 GLP-1 scare — with skill, capturing significant market share from Philips and proactively addressing the GLP-1 narrative with clinical data. Revenue roughly doubled from ~$3B (FY2020) to ~$4.9B (FY2025), with operating margins expanding materially as high-margin mask replacement revenue compounded.

The capital allocation blemish is the ~$1B MEDIFOX DAN acquisition (2022), which led to an ~$800M+ goodwill impairment in FY2024 — a clear value-destroyer in the SaaS segment. Brightree and MatrixCare have been adequate but not home runs. Share buybacks and a steadily growing dividend have been disciplined.

On governance: no financial restatements, no auditor disagreements, and no material fraud allegations per the FY2025 10-K. The Farrell family dynasty (founder Peter → son Mick) raises mild governance optics, but results earned the benefit of the doubt. Litigation exposure is routine for medtech; nothing existential. The CEO transition in 2025 introduces execution uncertainty, but the incoming leadership inherits a well-positioned business.

ResMed Inc. — Valuation

At $33.4B (22x trailing earnings), ResMed is fairly valued for a high-quality compounder — not a screaming bargain, but the entry price is reasonable for the business quality and growth trajectory.

The stock sits 21% below its 52-week high of $293.58, creating a more sensible entry than recent months. Here's the embedded math: trailing earnings are ~$1.5B, and at a forward P/E of 17.5x, the Street expects ~$1.9B in FY2027 earnings — a 27% jump that reflects continued Philips share retention and mask replacement pull-through. That forward number requires roughly 12-13% earnings growth per annum, which is achievable given FY2023-FY2025 earnings compounded at ~25%.

What's baked in? For a 10% annual total return over 5 years (including ~0.9% dividend yield and ~0.9% buyback yield), the stock needs ~8% annual price appreciation — implying ~$50B market cap by 2031. At a 20x terminal P/E, that demands ~$2.5B in earnings, or ~10% annual earnings growth. This is conservative relative to ResMed's recent trajectory.

Liquidation value is irrelevant here — tangible book is $2.46B against a $33.4B market cap. This is a going-concern valuation story. Net cash position ($1.21B cash vs. $0.85B debt) provides additional comfort.

Probability-weighted expected market cap: ~$48B, implying ~44% total upside over 5 years (~7.5% annualized + dividends). The bear case approximately equals today's price — the floor is well-supported by a $1.65B FCF run-rate at 20x.

ResMed doesn't provide quantitative revenue/earnings guidance, but management's track record of execution is strong — they navigated the Philips recall windfall expertly, converting temporary device share into permanent mask annuities. The GLP-1 overhang has mostly dissipated as evidence suggests weight-loss drugs expand OSA diagnoses rather than cannibalize PAP therapy.

ResMed — Long-term Valuation

ResMed is a textbook capital-light compounder trading at a reasonable price. At ~20× trailing FCF ($1.65B on a $33.4B market cap), the stock prices in mid-single-digit growth — yet the business is delivering 10% revenue growth with expanding margins and an enormous undiagnosed patient runway (~80% of sleep apnea sufferers globally).

The flywheel is self-reinforcing. Every device placed seeds years of recurring mask revenue (replaced every 3–6 months). Philips' 2021 recall permanently shifted millions of patients into ResMed's ecosystem; those patients are now generating annuity-like mask pulls. Capital intensity is trivial — $101M capex on $5.15B revenue (2%) — so operating income converts almost entirely to free cash. ROIC is high and rising as the Philips windfall matures through the installed base.

What erodes the moat first? Not GLP-1s — evidence consistently shows weight-loss drugs reduce OSA severity but don't eliminate it, and may actually increase diagnosis rates. The real risk is a credible competitor rebuilding share (Philips re-entering or a well-funded new entrant), or CMS reimbursement cuts compressing the economics. Neither appears imminent.

10-year math: 8–9% revenue CAGR (underpenetration + international expansion), stable 33%+ operating margins, 1–2% annual buyback accretion → earnings roughly double. At a maintained 20–22× multiple plus cumulative dividends, this maps to 2–2.5× over 10 years. Not a moonshot, but high-probability compounding with limited downside.

Thesis-breaking signal: Sustained quarterly decline in new patient setups (not mask resupply — new device placements), which would indicate the addressable market is shrinking rather than expanding.

ResMed Inc. — Risk Assessment

The single existential question for ResMed is whether GLP-1 weight-loss drugs will structurally shrink the addressable OSA market. The answer, based on clinical evidence through mid-2026, is no — but the narrative risk remains potent enough to periodically compress the multiple.

GLP-1 drugs are uncertainty, not permanent risk. The SURMOUNT-OSA trial showed tirzepatide reduced AHI scores but the vast majority of patients still had clinically significant OSA requiring PAP therapy. Obesity is one contributor to OSA alongside craniofacial anatomy, aging, and muscle tone — roughly 40% of OSA patients are non-obese. GLP-1 discontinuation causes near-complete weight regain. If anything, the heightened public attention on sleep health from GLP-1 discourse accelerates diagnosis in the ~80% of OSA sufferers who remain undiagnosed. This is a perception overhang, not a business impairment.

Philips re-entry is manageable. Philips' DreamStation recall handed ResMed 2-3 years of outsized share gains, now converting into recurring mask revenue. Philips is gradually returning but its brand credibility in sleep is permanently damaged; share normalization will be partial, not a full reversion.

Financial risk is minimal. ResMed generates robust FCF (~$1.5B+ annually), has been actively deleveraging, and carries net debt/EBITDA around 1x. The MatrixCare divestiture for $490M (FY2026) signals disciplined capital allocation, not distress. No liquidity or debt sustainability concerns exist.

Governance is clean. No fraud indicators, related-party concerns, or regulatory actions. Leadership transition from Mick Farrell (founder's son, long-tenured CEO) to new management has been orderly. Tariff exposure on Singapore manufacturing and FX volatility (AUD, EUR) create noise but not impairment.

The single risk that could permanently impair this business: A genuinely curative, mass-market, one-time treatment for OSA — not GLP-1s, which are chronic and don't cure it, but something like a gene therapy or a dramatically superior implantable device achieving CPAP-equivalent efficacy at scale. Probability over a 10-year horizon: low (~5-10%). The physics of upper airway collapse during sleep are not easily solved by a pill or a one-time procedure for the bulk of moderate-to-severe patients.

ResMed Inc. — Final Verdict

BUY. ResMed is a rare medtech compounder — dominant market position, capital-light economics, and a decade-long organic growth runway in a massively underdiagnosed disease. At 22x trailing earnings with the stock 21% below its 52-week high, the risk-reward favors ownership.

The business is exceptional. 60%+ flow-generator share in a structural duopoly, 61.6% gross margins, 24.3% ROE, and $1.65B in FY2025 FCF on just $100M of capex. The razors-and-blades model — devices create recurring mask revenue — generates predictable, high-quality cash flows. Philips' recall durably shifted share in ResMed's favor, and the 18M+ connected-device data moat compounds with every new patient. The undiagnosed patient pool (80%+ of moderate-to-severe OSA remains untreated) provides a long organic runway without requiring heroic assumptions.

Management is competent but imperfect. The MEDIFOX DAN acquisition (~$800M impairment) is the one clear blemish — a material capital allocation error in software adjacencies. The core device business has been managed excellently. Founder-family CEO provides long-term alignment, and the recent pivot to buybacks ($300M in FY2025) and portfolio pruning shows corrective discipline.

Valuation is fair, not cheap. $33.4B market cap against $1.4B net income and $1.65B FCF gives trailing multiples of ~22x earnings and ~20x FCF. The expected case of ~$48B by 2031 implies ~7-8% annualized price appreciation plus a ~1% dividend yield — an 8-9% total return. Adequate for a business of this quality, but not a fat pitch.

Strongest counterargument: GLP-1 weight-loss drugs could structurally reduce the OSA-eligible population. The evidence so far suggests these drugs are additive (weight loss increases diagnosis rates, many patients still need CPAP post-weight-loss), but this remains a real long-term uncertainty worth monitoring. Second-order risk: the ~20x FCF multiple leaves limited margin of safety if growth decelerates below mid-single digits.

For existing holders: Hold. The business continues to compound intrinsic value; there's no reason to sell at these levels. Add on meaningful pullbacks toward $200 or below.

Position sizing: Build in small tranches. This is a high-quality compounder at fair value — not a once-in-a-lifetime entry. Allocate 2-3% initially, add on weakness.

Is this analysis complete? Mostly. Further research should focus on: (1) GLP-1 real-world data — track Wegovy/Zepbound impact on CPAP prescription volumes over the next 2-3 quarters; (2) MEDIFOX DAN disposition — is management pursuing a sale or wind-down, and what's the residual value?; (3) competitive pipeline — any emerging alternatives to CPAP (hypoglossal nerve stimulation adoption curves, oral appliance innovation).